1.2011年10月22日-25日，美国眼科学年会在美国佛罗里达州的奥多兰举行，图为奥多治会议中心。
（1.The Orange County Convention Center in Orlando, Florida, played host to the American Academy of Ophthalmology （AAO） 2011 Annual Meeting, held October 22 to 25, 2011.）
${FDPageBreak}
2.今年会议的亮点是：
（1）飞秒激光辅助白内障手术被视为“重大进展”
（2）MRSA眼部感染呈上升趋势，但治疗滞后
（3）青光眼患者用药依从性差异很大
（4）眼保健医生比家庭医生有更多筋骨劳伤的苦恼
（5）白内障手术有助于阿尔茨海默氏症患者
（6）iPad有助于提高视力不佳患者的阅读能力
（2.Among this year's highlights:
（1）Femtosecond laser-assisted cataract surgery is seen as a “major advance”
（2）MRSA eye infections are on the rise, but treatment is lagging
（3）Medication compliance in patients with glaucoma varies widely
（4）Eye-care physicians have more musculoskeletal woes than family physicians
（5）Cataract surgery helps patients with Alzheimer's disease
（6）The iPad improves the reading ability of patients with low vision）
${FDPageBreak}
3.飞秒激光助白内障手术一臂之力
（3.Femtosecond Laser-Assisted Cataract Surgery a Major Advance
A study provides strong evidence of the increased safety and effectiveness of laser-mediated emulsification of cataracts compared with phacoemulsification. The approach uses femtosecond laser technology, which delivers near-infrared light to create precise subsurface cuts at depths that are greater than those possible using conventional approaches. Stephen Slade, MD, from Slade & Baker Vision Center in Houston, Texas, who was not involved in the study, described this technique as “the single most significant advancement in cataract surgery in the last 40 years.”）
${FDPageBreak}
4.Novel眼插入改善糖尿病性黄斑水肿
（4.Novel Eye Insert Improves Diabetic Macular Edema
An intravitreal insert that releases a sustained and controlled amount of the corticosteroid fluocinolone acetonide improved visual acuity for as long as 3 years in a study of patients with diabetic macular edema. This result “is particularly exciting, as it demonstrates that a single insert can provide rapid and sustained improvement in visual acuity for up to 36 months,” said David Brown, MD, from Retinal Consultants of Houston, Methodist Hospital, Texas, during his presentation.）
${FDPageBreak}
5.视网膜中央静脉阻塞1年新药物可维持视力
（5.New Drug Maintains Visual Acuity in Central Retinal Vein Occlusion at 1 Year
Patients with macular edema caused by central retinal vein occlusion who received injections of VEGF Trap-Eye （Regeneron Pharmaceuticals） on an as-needed basis after receiving the drug once a month for 6 months maintained their initially improved visual acuity, according to 1-year results of the COPERNICUS trial. “This is good information. VEGF Trap-Eye works and appears to have some durability of effect when given on an as-needed basis,” said study presenter Julia Haller, MD, ophthalmologist-in-chief at the Wills Eye Institute and professor and chair of the Department of Ophthalmology at Thomas Jefferson University in Philadelphia, Pennsylvania.）
